Cancer drugs in US are ‘not affordable,’ says German study, which suggests setting drug prices by indication
US policymakers and payers should consider indication-based pricing in a bid to cut down on higher cancer drug costs in the US, according to research recently published by two German oncologists.
The study, published last month, looked at how cancer drugs approved for multiple indications are priced in the US.
“New cancer drugs are not affordable in the United States,” the authors wrote, after analyzing 145 FDA-approved cancer drugs with 373 total indications. Cancer drugs cost an average of $24,000 a month and have a median monthly price of $16,000. More than 95% of these drugs cost more than $10,000 a month.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
